A prospective, randomized, open-label, controlled trial to compare the safety, tolerability and efficacy of influenza virus vaccine, trivalent, type A and B, live, cold-adapted (CAIV-T) [influenza virus vaccine live] with influenza virus vaccine, trivalent, inactivated (TIV) in children with a history of recurrent respiratory tract infections aged 6 months to less than 72 months

Trial Profile

A prospective, randomized, open-label, controlled trial to compare the safety, tolerability and efficacy of influenza virus vaccine, trivalent, type A and B, live, cold-adapted (CAIV-T) [influenza virus vaccine live] with influenza virus vaccine, trivalent, inactivated (TIV) in children with a history of recurrent respiratory tract infections aged 6 months to less than 72 months

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2012

At a glance

  • Drugs Influenza virus vaccine; Influenza virus vaccine live
  • Indications Influenza virus infections; Respiratory tract infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 04 Dec 2006 Status change
    • 09 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top